Go Pro

Medtronic (MDT) Financials

Medtronic logo
$83.07 -0.12 (-0.15%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$83.25 +0.18 (+0.22%)
As of 07/2/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Medtronic

Annual Income Statements for Medtronic

This table shows Medtronic's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/29/2016 4/28/2017 4/27/2018 4/26/2019 4/24/2020 4/30/2021 4/29/2022 4/28/2023 4/26/2024 4/25/2025 4/24/2026
Net Income / (Loss) Attributable to Common Shareholders
3,538 4,028 3,104 4,631 4,789 3,606 5,039 3,758 3,676 4,662 4,801
Consolidated Net Income / (Loss)
3,538 4,024 3,095 4,650 4,806 3,630 5,062 3,784 3,705 4,691 4,837
Net Income / (Loss) Continuing Operations
3,538 4,024 3,095 4,650 4,806 3,630 5,061 3,784 3,704 4,692 4,837
Total Pre-Tax Income
4,336 4,602 5,675 5,197 4,055 3,895 5,517 5,364 4,837 5,628 6,136
Total Operating Income
5,361 5,383 6,640 6,268 4,791 4,484 5,752 5,485 5,144 5,955 6,467
Total Gross Profit
19,691 20,416 20,886 21,402 19,489 19,634 21,541 20,508 21,148 21,905 23,643
Total Revenue
28,833 29,710 29,953 30,557 28,913 30,117 31,686 31,227 32,364 33,537 36,364
Operating Revenue
28,833 29,710 29,953 30,557 28,913 30,117 31,686 31,227 32,364 33,537 36,364
Total Cost of Revenue
9,142 9,294 9,067 9,155 9,424 10,483 10,145 10,719 11,216 11,632 12,721
Operating Cost of Revenue
9,142 9,294 9,067 9,155 9,424 10,483 10,145 10,719 11,216 11,632 12,721
Total Operating Expenses
14,330 15,033 14,246 15,134 14,698 15,150 15,788 15,023 16,003 15,949 17,177
Selling, General & Admin Expense
9,469 10,018 10,238 10,418 10,109 10,148 10,292 10,415 10,736 10,849 11,784
Research & Development Expense
2,224 2,193 2,256 2,330 2,331 2,493 2,746 2,696 2,735 2,732 2,873
Amortization Expense
1,931 1,980 1,823 1,764 1,756 1,783 1,733 1,698 1,693 1,807 1,772
Other Operating Expenses / (Income)
107 239 -162 258 71 315 862 -131 464 -23 386
Restructuring Charge
573 303 30 198 118 293 60 375 226 267 249
Other Special Charges / (Income)
26 300 61 166 313 118 95 -30 149 317 113
Total Other Income / (Expense), net
-1,025 -781 -965 -1,071 -736 -589 -235 -121 -307 -327 -331
Interest Expense
1,386 1,094 1,146 1,444 1,092 925 553 636 719 729 715
Other Income / (Expense), net
-70 313 181 373 356 336 318 515 412 402 384
Income Tax Expense
798 578 2,580 547 -751 265 456 1,580 1,133 936 1,299
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 -4.00 -9.00 19 17 24 22 26 28 29 37
Basic Earnings per Share
$2.51 $2.92 $2.29 $3.44 $3.57 $2.68 $3.75 $2.83 $2.77 $3.63 $3.75
Weighted Average Basic Shares Outstanding
1.41B 1.38B 1.36B 1.35B 1.34B 1.34B 1.34B 1.33B 1.33B 1.29B 1.28B
Diluted Earnings per Share
$2.48 $2.89 $2.27 $3.41 $3.54 $2.66 $3.73 $2.82 $2.76 $3.61 $3.73
Weighted Average Diluted Shares Outstanding
1.43B 1.39B 1.37B 1.36B 1.35B 1.35B 1.35B 1.33B 1.33B 1.29B 1.29B
Weighted Average Basic & Diluted Shares Outstanding
1.41B 1.38B 1.36B 1.35B 1.34B 1.34B 1.33B 1.33B 1.28B 1.28B 1.28B
Cash Dividends to Common per Share
$1.52 $1.72 $1.84 $2.00 $2.16 $2.32 $2.52 $2.72 $2.76 $2.80 $2.84

Quarterly Income Statements for Medtronic

This table shows Medtronic's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 10/27/2023 1/26/2024 4/26/2024 7/26/2024 10/25/2024 1/24/2025 4/25/2025 7/25/2025 10/24/2025 1/23/2026 4/24/2026
Net Income / (Loss) Attributable to Common Shareholders
909 1,322 654 1,042 1,270 1,294 1,056 1,040 1,374 1,143 1,244
Consolidated Net Income / (Loss)
911 1,337 660 1,049 1,278 1,303 1,061 1,047 1,381 1,150 1,259
Net Income / (Loss) Continuing Operations
911 1,337 660 1,048 1,278 1,303 1,063 1,047 1,382 1,150 1,258
Total Pre-Tax Income
1,313 1,472 856 1,268 1,559 1,540 1,261 1,302 1,597 1,404 1,833
Total Operating Income
1,340 1,483 1,053 1,278 1,595 1,646 1,436 1,445 1,686 1,464 1,872
Total Gross Profit
5,223 5,307 5,544 5,154 5,457 5,513 5,781 5,577 5,900 5,756 6,410
Total Revenue
7,984 8,089 8,589 7,915 8,403 8,292 8,927 8,578 8,961 9,017 9,808
Operating Revenue
7,984 8,089 8,589 7,915 8,403 8,292 8,927 8,578 8,961 9,017 9,808
Total Cost of Revenue
2,761 2,782 3,045 2,761 2,946 2,779 3,146 3,001 3,061 3,261 3,398
Operating Cost of Revenue
2,761 2,782 3,045 2,761 2,946 2,779 3,146 3,001 3,061 3,261 3,398
Total Operating Expenses
3,883 3,824 4,491 3,874 3,863 3,868 4,344 4,133 4,214 4,293 4,537
Selling, General & Admin Expense
2,686 2,673 2,764 2,655 2,757 2,717 2,720 2,806 2,965 2,956 3,057
Research & Development Expense
698 695 674 676 697 675 684 726 754 722 671
Amortization Expense
425 419 420 414 413 416 564 459 463 441 409
Other Operating Expenses / (Income)
-31 17 477 1.00 -34 -5.00 15 70 22 35 259
Restructuring Charge
40 20 112 47 30 43 147 45 10 77 117
Other Special Charges / (Income)
65 0.00 44 81 0.00 22 214 27 0.00 62 24
Total Other Income / (Expense), net
-26 -11 -198 -10 -36 -107 -174 -143 -89 -60 -39
Interest Expense
180 188 203 167 209 179 174 176 181 181 177
Other Income / (Expense), net
154 177 5.00 157 173 72 - 33 92 121 138
Income Tax Expense
402 135 196 220 281 237 198 255 215 254 575
Net Income / (Loss) Attributable to Noncontrolling Interest
2.00 15 5.00 6.00 9.00 9.00 5.00 7.00 7.00 6.00 17
Basic Earnings per Share
$0.68 $0.99 $0.51 $0.81 $0.99 $1.01 $0.82 $0.81 $1.07 $0.89 $0.98
Weighted Average Basic Shares Outstanding
1.33B 1.33B 1.33B 1.29B 1.28B 1.28B 1.29B 1.28B 1.28B 1.28B 1.28B
Diluted Earnings per Share
$0.68 $0.99 $0.50 $0.80 $0.99 $1.01 $0.81 $0.81 $1.07 $0.89 $0.96
Weighted Average Diluted Shares Outstanding
1.33B 1.33B 1.33B 1.30B 1.29B 1.29B 1.29B 1.29B 1.29B 1.29B 1.29B
Weighted Average Basic & Diluted Shares Outstanding
1.33B 1.33B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B

Annual Cash Flow Statements for Medtronic

This table details how cash moves in and out of Medtronic's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/29/2016 4/28/2017 4/27/2018 4/26/2019 4/24/2020 4/30/2021 4/29/2022 4/28/2023 4/26/2024 4/25/2025 4/24/2026
Net Change in Cash & Equivalents
-1,967 2,091 -1,298 724 -253 -547 121 -2,171 -259 934 -269
Net Cash From Operating Activities
5,218 6,880 4,684 7,007 7,234 6,240 7,346 6,039 6,787 7,044 7,330
Net Cash From Continuing Operating Activities
5,218 6,880 4,684 7,007 7,234 6,240 7,346 6,039 6,787 7,044 7,330
Net Income / (Loss) Continuing Operations
3,538 4,024 3,095 4,650 4,806 3,630 5,062 3,784 3,705 4,691 4,837
Consolidated Net Income / (Loss)
3,538 4,024 3,095 4,650 4,806 3,630 5,062 3,784 3,705 4,691 4,837
Depreciation Expense
2,820 2,917 2,644 2,659 2,663 2,702 2,707 2,697 2,647 2,861 2,958
Non-Cash Adjustments To Reconcile Net Income
694 259 37 1,082 1,019 1,031 1,070 751 1,427 862 907
Changes in Operating Assets and Liabilities, net
-1,863 -320 -1,092 -1,384 -1,254 -1,123 -1,493 -1,193 -992 -1,370 -1,372
Net Cash From Investing Activities
2,245 -1,571 5,858 -774 -3,203 -2,866 -1,659 -3,493 -2,366 -1,937 -2,934
Net Cash From Continuing Investing Activities
2,245 -1,571 5,858 -774 -3,203 -2,866 -1,659 -3,493 -2,366 -1,937 -2,934
Purchase of Property, Plant & Equipment
-1,046 -1,254 -1,068 -1,134 -1,213 -1,355 -1,368 -1,459 -1,587 -1,859 -1,904
Acquisitions
-1,213 -1,324 -137 -1,827 -488 -994 -91 -1,867 -211 -98 -406
Purchase of Investments
-5,406 -4,371 -3,200 -2,532 -11,039 -11,808 -9,882 -7,514 -7,748 -8,226 -8,725
Sale and/or Maturity of Investments
9,924 5,356 4,227 4,683 9,574 11,345 9,692 7,343 7,441 8,495 8,105
Other Investing Activities, net
-14 22 -22 36 -37 -54 -10 4.00 -261 -249 -4.00
Net Cash From Financing Activities
-9,543 -3,283 -11,954 -5,431 -4,198 -4,136 -5,336 -4,960 -4,450 -4,361 -4,751
Net Cash From Continuing Financing Activities
-9,543 -3,283 -11,954 -5,431 -4,198 -4,136 -5,336 -4,960 -4,450 -4,361 -4,750
Repayment of Debt
-5,182 -863 -7,713 -8,661 -6,208 -10,488 162 -8,700 1,070 -1,254 -2,877
Repurchase of Common Equity
-2,830 -3,544 -2,171 -2,877 -1,326 -652 -2,544 -645 -2,138 -3,235 -1,035
Payment of Dividends
-2,139 -2,376 -2,494 -2,693 -2,894 -3,120 -3,383 -3,616 -3,666 -3,589 -3,639
Issuance of Debt
139 3,072 21 7,808 5,568 9,650 0.00 7,693 0.00 3,209 1,747
Issuance of Common Equity
491 428 403 992 662 474 429 308 284 508 1,054
Effect of Exchange Rate Changes
113 - - - - - -231 - -230 188 85
Cash Interest Paid
1,266 1,134 1,147 973 643 582 540 606 826 762 774
Cash Income Taxes Paid
1,379 1,029 2,542 1,558 878 1,250 996 1,548 1,622 1,819 1,942

Quarterly Cash Flow Statements for Medtronic

This table details how cash moves in and out of Medtronic's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 10/27/2023 1/26/2024 4/26/2024 7/26/2024 10/25/2024 1/24/2025 4/25/2025 7/25/2025 10/24/2025 1/23/2026 4/24/2026
Net Change in Cash & Equivalents
-28 312 -339 27 83 -154 978 -945 9.00 -136 803
Net Cash From Operating Activities
661 2,474 2,777 986 958 2,572 2,528 1,088 925 2,744 2,573
Net Cash From Continuing Operating Activities
661 2,474 2,777 986 958 2,572 2,528 1,088 925 2,743 2,574
Net Income / (Loss) Continuing Operations
911 1,337 660 1,049 1,278 1,303 1,061 1,047 1,381 1,150 1,259
Consolidated Net Income / (Loss)
911 1,337 660 1,049 1,278 1,303 1,061 1,047 1,381 1,150 1,259
Depreciation Expense
672 649 654 662 675 684 840 748 745 749 716
Non-Cash Adjustments To Reconcile Net Income
209 192 797 92 97 261 412 273 228 243 163
Changes in Operating Assets and Liabilities, net
-1,131 296 666 -817 -1,092 324 215 -980 -1,429 601 436
Net Cash From Investing Activities
-424 -707 -696 -259 -345 -843 -490 -719 -482 -816 -917
Net Cash From Continuing Investing Activities
-424 -707 -696 -259 -345 -843 -490 -719 -482 -815 -918
Purchase of Property, Plant & Equipment
-461 -346 -426 -520 -404 -476 -459 -504 -468 -444 -488
Acquisitions
- -52 -137 - - -98 - - - - -406
Purchase of Investments
-1,487 -2,019 -2,326 -1,879 -2,140 -2,074 -2,133 -2,100 -2,101 -2,371 -2,153
Sale and/or Maturity of Investments
1,588 1,806 2,299 2,157 2,181 1,917 2,240 2,010 1,948 2,024 2,123
Other Investing Activities, net
-42 -96 -106 -17 18 -112 -138 -125 139 -24 6.00
Net Cash From Financing Activities
-90 -1,500 -2,359 -731 -534 -1,753 -1,343 -1,381 -395 -2,087 -888
Net Cash From Continuing Financing Activities
-90 -1,500 -2,359 -731 -534 -1,753 -1,343 -1,381 -395 -2,086 -888
Repayment of Debt
-339 813 104 -639 575 160 -1,350 -443 -1,020 -1,234 -180
Repurchase of Common Equity
-226 -132 -1,628 -2,492 -288 -181 -274 -123 -372 -105 -435
Payment of Dividends
-918 -917 -913 -898 -897 -897 -897 -910 -910 -911 -908
Issuance of Common Equity
72 57 78 89 143 168 108 95 160 164 635
Cash Interest Paid
392 92 258 119 394 54 195 81 461 31 201
Cash Income Taxes Paid
993 293 219 394 941 180 304 402 992 204 344

Annual Balance Sheets for Medtronic

This table presents Medtronic's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/29/2016 4/28/2017 4/27/2018 4/26/2019 4/24/2020 4/30/2021 4/29/2022 4/28/2023 4/26/2024 4/25/2025 4/24/2026
Total Assets
99,644 99,857 91,393 89,694 90,689 93,083 90,981 90,948 89,981 91,680 93,028
Total Current Assets
23,600 24,873 22,980 21,967 22,031 22,548 23,059 21,675 21,935 23,814 24,787
Cash & Equivalents
2,876 4,967 3,669 4,393 4,140 3,593 3,714 1,543 1,284 2,218 1,949
Short-Term Investments
9,758 8,741 7,558 5,455 6,808 7,224 6,859 6,416 6,721 6,747 7,271
Accounts Receivable
5,562 5,591 5,987 6,222 4,645 5,462 5,551 5,998 6,128 6,515 6,643
Inventories, net
3,473 3,338 3,579 3,753 4,229 4,313 4,616 5,293 5,217 5,476 5,951
Other Current Assets
- 1,865 2,187 2,144 2,209 1,955 2,318 2,425 2,584 2,858 2,972
Plant, Property, & Equipment, net
4,841 4,361 4,604 4,675 4,828 0.00 5,413 5,569 6,131 6,837 7,417
Total Noncurrent Assets
71,203 70,623 63,809 63,052 63,830 70,534 62,508 63,705 61,915 61,028 60,823
Goodwill
41,500 38,515 39,543 39,959 39,841 41,961 40,502 41,425 40,986 41,737 42,587
Intangible Assets
26,899 23,407 21,723 20,560 19,063 17,740 15,595 14,844 13,225 11,667 10,146
Noncurrent Deferred & Refundable Income Taxes
1,383 1,550 1,465 1,519 2,832 3,169 3,403 3,477 3,657 4,040 3,943
Other Noncurrent Operating Assets
1,421 1,232 1,078 1,014 2,094 7,664 3,008 3,959 4,047 3,584 4,147
Total Liabilities & Shareholders' Equity
99,644 99,857 91,393 89,694 90,689 93,083 90,981 90,948 89,981 91,680 93,028
Total Liabilities
47,581 49,527 40,571 39,482 39,817 41,481 38,260 39,283 39,561 43,424 42,956
Total Current Liabilities
7,165 14,264 10,084 8,472 10,366 8,509 12,394 9,051 10,789 12,879 11,658
Short-Term Debt
993 7,520 2,058 838 2,776 11 3,742 20 1,092 2,874 1,788
Accounts Payable
1,709 1,555 1,628 1,953 1,996 2,106 2,276 2,662 2,410 2,449 2,644
Current Deferred & Payable Income Tax Liabilities
566 633 979 567 502 435 704 840 1,330 1,358 914
Current Employee Benefit Liabilities
1,712 1,904 1,988 2,189 2,099 2,482 2,121 1,949 2,375 2,514 2,678
Other Current Liabilities
2,185 2,618 3,431 2,925 2,993 3,475 3,551 3,581 3,582 3,683 3,634
Total Noncurrent Liabilities
40,416 35,263 30,487 31,010 29,451 32,970 25,866 30,232 28,772 30,546 31,298
Long-Term Debt
30,109 25,921 23,699 24,486 22,021 26,378 20,372 24,344 23,932 25,642 26,173
Noncurrent Deferred Revenue
2,903 2,405 3,051 2,838 2,682 2,251 2,087 2,360 1,859 1,574 1,515
Noncurrent Deferred & Payable Income Tax Liabilities
3,729 2,978 1,423 1,278 1,174 1,028 884 708 515 403 362
Noncurrent Employee Benefit Liabilities
1,759 1,724 1,425 1,651 1,910 1,557 1,113 1,093 1,101 1,158 1,193
Other Noncurrent Operating Liabilities
1,916 1,515 889 757 1,664 1,756 1,410 1,727 1,365 1,769 2,055
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
52,063 50,330 50,822 50,212 50,872 51,602 52,722 51,665 50,420 48,256 50,072
Total Preferred & Common Equity
52,063 50,208 50,720 50,091 50,737 51,428 52,551 51,483 50,214 48,024 49,463
Total Common Equity
52,063 50,208 50,720 50,091 50,737 51,428 52,551 51,483 50,214 48,025 49,463
Common Stock
32,227 29,551 28,127 26,532 26,165 26,319 24,566 24,590 23,129 20,833 20,926
Retained Earnings
21,704 23,270 24,379 26,270 28,132 28,594 30,250 30,392 30,403 31,476 32,638
Accumulated Other Comprehensive Income / (Loss)
-1,868 -2,613 -1,786 -2,711 -3,560 -3,485 -2,265 -3,499 -3,318 -4,284 -4,101
Noncontrolling Interest
0.00 122 102 121 135 174 171 182 206 232 609

Quarterly Balance Sheets for Medtronic

This table presents Medtronic's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 4/28/2023 7/28/2023 10/27/2023 1/26/2024 4/26/2024 7/26/2024 10/25/2024 1/24/2025 7/25/2025 10/24/2025 1/23/2026
Total Assets
90,948 90,776 90,087 90,836 89,981 89,749 90,042 89,973 90,972 91,346 91,485
Total Current Assets
21,675 21,869 22,081 22,513 21,935 21,947 22,438 22,513 23,223 23,996 24,071
Cash & Equivalents
1,543 1,339 1,311 1,623 1,284 1,311 1,394 1,240 1,273 1,282 1,147
Short-Term Investments
6,416 6,537 6,423 6,698 6,721 6,532 6,595 6,682 6,848 7,045 7,236
Accounts Receivable
5,998 5,806 5,934 5,968 6,128 6,011 6,260 6,115 6,263 6,389 6,359
Inventories, net
5,293 5,668 5,754 5,726 5,217 5,414 5,479 5,610 5,886 6,156 6,309
Other Current Assets
2,425 2,518 2,658 2,499 2,584 2,679 2,710 2,865 2,952 3,124 3,020
Plant, Property, & Equipment, net
5,569 5,665 5,735 5,838 6,131 6,282 6,438 6,593 7,006 7,164 7,179
Total Noncurrent Assets
63,705 63,243 62,271 62,485 61,915 61,519 61,165 60,867 60,744 60,186 60,235
Goodwill
41,425 41,436 40,821 41,160 40,986 41,084 41,161 40,819 42,007 41,811 41,892
Intangible Assets
14,844 14,434 14,060 13,690 13,225 12,819 12,423 12,184 11,223 10,770 10,335
Noncurrent Deferred & Refundable Income Taxes
3,477 3,461 3,428 3,599 3,657 3,554 3,572 3,614 3,929 3,857 3,967
Other Noncurrent Operating Assets
3,959 3,912 3,962 4,036 4,047 4,062 4,009 4,250 3,585 3,748 4,041
Total Liabilities & Shareholders' Equity
90,948 90,776 90,087 90,836 89,981 89,749 90,042 89,973 90,972 91,346 91,485
Total Liabilities
39,283 39,410 38,440 38,840 39,561 41,589 41,326 40,358 42,839 42,489 42,289
Total Current Liabilities
9,051 9,047 9,659 9,793 10,789 10,287 12,195 11,840 11,530 9,935 9,495
Short-Term Debt
20 519 1,339 1,029 1,092 1,553 3,719 2,622 2,430 1,420 191
Accounts Payable
2,662 2,239 2,174 1,992 2,410 2,291 2,376 2,286 2,555 2,581 2,569
Current Deferred & Payable Income Tax Liabilities
840 1,013 1,088 1,109 1,330 1,063 947 1,125 933 650 650
Current Employee Benefit Liabilities
1,949 1,695 1,758 2,174 2,375 1,776 1,893 2,281 2,017 2,130 2,581
Other Current Liabilities
3,581 3,581 3,299 3,488 3,582 3,604 3,260 3,526 3,596 3,153 3,504
Total Noncurrent Liabilities
30,232 30,364 28,780 29,048 28,772 31,302 29,130 28,518 31,309 32,553 32,793
Long-Term Debt
24,344 24,463 23,741 24,153 23,932 26,312 24,607 23,985 26,179 27,680 27,880
Noncurrent Deferred Revenue
2,360 2,407 1,777 1,821 1,859 1,917 1,432 1,485 1,722 1,539 1,587
Noncurrent Deferred & Payable Income Tax Liabilities
708 687 686 615 515 496 473 452 416 386 365
Noncurrent Employee Benefit Liabilities
1,093 1,092 1,020 1,049 1,101 1,107 1,084 1,063 1,179 1,184 1,191
Other Noncurrent Operating Liabilities
1,727 1,715 1,556 1,410 1,365 1,470 1,534 1,533 1,813 1,764 1,770
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
51,665 51,366 51,647 51,996 50,420 48,160 48,716 49,615 48,133 48,857 49,196
Total Preferred & Common Equity
51,483 51,178 51,460 51,792 50,214 47,947 48,494 49,387 47,893 48,652 48,985
Total Common Equity
51,483 51,178 51,459 51,791 50,214 47,947 48,493 49,388 47,893 48,652 48,985
Common Stock
24,590 24,587 24,580 24,589 23,129 20,810 20,824 20,910 20,891 20,857 21,012
Retained Earnings
30,392 30,265 30,256 30,661 30,403 30,547 30,919 31,317 31,606 32,070 32,303
Accumulated Other Comprehensive Income / (Loss)
-3,499 -3,674 -3,377 -3,459 -3,318 -3,410 -3,250 -2,839 -4,604 -4,275 -4,330
Noncontrolling Interest
182 188 187 204 206 213 222 228 240 204 211

Annual Metrics And Ratios for Medtronic

This table displays calculated financial ratios and metrics derived from Medtronic's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 4/29/2016 4/28/2017 4/27/2018 4/26/2019 4/24/2020 4/30/2021 4/29/2022 4/28/2023 4/26/2024 4/25/2025 4/24/2026
DEI Shares Outstanding
- - - - - - - - - - 1,283,884,964.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 1,283,884,964.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 3.74
Growth Metrics
- - - - - - - - - - -
Revenue Growth
42.31% 3.04% 0.82% 2.02% -5.38% 4.16% 5.21% -1.45% 3.64% 3.62% 8.43%
EBITDA Growth
58.12% 5.81% 9.89% -1.74% -16.02% -3.69% 16.68% -0.91% -5.68% 12.37% 6.41%
EBIT Growth
40.49% 7.65% 19.75% -2.64% -22.50% -6.35% 25.93% -1.15% -7.40% 14.42% 7.77%
NOPAT Growth
51.37% 7.60% -23.06% 54.87% 1.25% -26.41% 26.27% -26.67% 1.80% 26.03% 2.69%
Net Income Growth
32.26% 13.74% -23.09% 50.24% 3.35% -24.47% 39.45% -25.25% -2.09% 26.61% 3.11%
EPS Growth
2.90% 16.53% -21.45% 50.22% 3.81% -24.86% 40.23% -24.40% -2.13% 30.80% 3.32%
Operating Cash Flow Growth
6.45% 31.85% -31.92% 49.59% 3.24% -13.74% 17.72% -17.79% 12.39% 3.79% 4.06%
Free Cash Flow Firm Growth
107.57% 183.41% -73.89% 88.55% 26.04% -74.03% 258.68% -66.73% 121.97% 0.56% -10.96%
Invested Capital Growth
0.85% -8.51% 1.28% 0.51% -1.47% 3.79% -1.36% 2.73% -0.93% 0.55% 1.48%
Revenue Q/Q Growth
0.92% 1.19% 0.77% 0.01% -6.92% 7.85% -0.31% 1.48% 0.14% 1.02% 2.48%
EBITDA Q/Q Growth
16.67% 4.92% 12.72% -0.31% -17.34% 21.91% 0.48% -0.18% -7.91% 6.52% 4.81%
EBIT Q/Q Growth
27.22% 8.00% 19.69% -0.48% -24.20% 38.51% 0.63% -0.12% -10.90% 6.32% 9.14%
NOPAT Q/Q Growth
46.45% -3.14% 22.47% -7.86% -14.99% 14.13% 3.08% -8.35% -8.94% 8.50% 1.32%
Net Income Q/Q Growth
45.36% 1.54% 10.77% -5.74% -10.15% 25.04% 2.57% -7.44% -12.49% 9.35% 4.27%
EPS Q/Q Growth
73.43% 2.12% 11.82% -6.06% -9.92% 24.88% 2.75% -7.24% -12.10% 9.39% 4.19%
Operating Cash Flow Q/Q Growth
-10.10% 6.95% -13.56% 17.61% -8.09% 4.96% 4.44% 7.15% 4.90% -3.41% 0.62%
Free Cash Flow Firm Q/Q Growth
0.00% 165.15% -66.78% 5.83% 0.57% -41.48% 21.73% -8.83% 12.12% -10.48% -7.93%
Invested Capital Q/Q Growth
1.68% -8.06% 0.97% -0.21% -1.79% 0.84% -0.58% -0.79% -2.06% -0.72% -0.11%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
68.29% 68.72% 69.73% 70.04% 67.41% 65.19% 67.98% 65.67% 65.34% 65.32% 65.02%
EBITDA Margin
28.23% 28.99% 31.60% 30.43% 27.01% 24.98% 27.70% 27.85% 25.35% 27.49% 26.97%
Operating Margin
18.59% 18.12% 22.17% 20.51% 16.57% 14.89% 18.15% 17.56% 15.89% 17.76% 17.78%
EBIT Margin
18.35% 19.17% 22.77% 21.73% 17.80% 16.00% 19.16% 19.21% 17.17% 18.96% 18.84%
Profit (Net Income) Margin
12.27% 13.54% 10.33% 15.22% 16.62% 12.05% 15.98% 12.12% 11.45% 13.99% 13.30%
Tax Burden Percent
81.60% 87.44% 54.54% 89.47% 118.52% 93.20% 91.75% 70.54% 76.60% 83.35% 78.83%
Interest Burden Percent
81.95% 80.79% 83.20% 78.26% 78.78% 80.81% 90.89% 89.40% 87.06% 88.53% 89.56%
Effective Tax Rate
18.40% 12.56% 45.46% 10.53% -18.52% 6.80% 8.27% 29.46% 23.42% 16.63% 21.17%
Return on Invested Capital (ROIC)
6.23% 6.97% 5.58% 8.56% 8.71% 6.34% 7.91% 5.76% 5.81% 7.34% 7.46%
ROIC Less NNEP Spread (ROIC-NNEP)
1.47% 2.79% 1.91% 2.17% 2.76% 2.61% 6.43% 5.19% 4.41% 5.85% 6.10%
Return on Net Nonoperating Assets (RNNOA)
0.49% 0.89% 0.54% 0.65% 0.80% 0.75% 1.80% 1.49% 1.44% 2.17% 2.38%
Return on Equity (ROE)
6.72% 7.86% 6.12% 9.20% 9.51% 7.08% 9.70% 7.25% 7.26% 9.51% 9.84%
Cash Return on Invested Capital (CROIC)
5.38% 15.86% 4.31% 8.05% 10.19% 2.62% 9.28% 3.07% 6.75% 6.80% 5.99%
Operating Return on Assets (OROA)
5.13% 5.71% 7.13% 7.33% 5.71% 5.25% 6.60% 6.60% 6.14% 7.00% 7.42%
Return on Assets (ROA)
3.43% 4.03% 3.24% 5.14% 5.33% 3.95% 5.50% 4.16% 4.10% 5.16% 5.24%
Return on Common Equity (ROCE)
6.72% 7.85% 6.11% 9.18% 9.48% 7.06% 9.67% 7.23% 7.23% 9.47% 9.75%
Return on Equity Simple (ROE_SIMPLE)
6.80% 8.01% 6.10% 9.28% 9.47% 7.06% 9.63% 7.35% 7.38% 9.77% 0.00%
Net Operating Profit after Tax (NOPAT)
4,374 4,707 3,621 5,608 5,678 4,179 5,277 3,869 3,939 4,965 5,098
NOPAT Margin
15.17% 15.84% 12.09% 18.35% 19.64% 13.88% 16.65% 12.39% 12.17% 14.80% 14.02%
Net Nonoperating Expense Percent (NNEP)
4.76% 4.18% 3.66% 6.39% 5.95% 3.73% 1.47% 0.57% 1.40% 1.50% 1.36%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - - 6.47% 6.53%
Cost of Revenue to Revenue
31.71% 31.28% 30.27% 29.96% 32.59% 34.81% 32.02% 34.33% 34.66% 34.68% 34.98%
SG&A Expenses to Revenue
32.84% 33.72% 34.18% 34.09% 34.96% 33.70% 32.48% 33.35% 33.17% 32.35% 32.41%
R&D to Revenue
7.71% 7.38% 7.53% 7.63% 8.06% 8.28% 8.67% 8.63% 8.45% 8.15% 7.90%
Operating Expenses to Revenue
49.70% 50.60% 47.56% 49.53% 50.84% 50.30% 49.83% 48.11% 49.45% 47.56% 47.24%
Earnings before Interest and Taxes (EBIT)
5,291 5,696 6,821 6,641 5,147 4,820 6,070 6,000 5,556 6,357 6,851
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
8,140 8,613 9,465 9,300 7,810 7,522 8,777 8,697 8,203 9,218 9,809
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.76 1.91 1.88 2.07 2.37 3.17 2.49 2.27 2.11 2.25 2.16
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.18 3.24 3.18 3.39 4.16 5.41 4.14 3.75 3.27 3.22 2.94
Price to Earnings (P/E)
25.94 23.87 30.68 22.36 25.09 45.18 26.01 31.16 28.80 23.15 22.28
Dividend Yield
2.32% 2.45% 2.62% 2.59% 2.41% 1.92% 2.58% 3.09% 3.46% 3.33% 3.41%
Earnings Yield
3.86% 4.19% 3.26% 4.47% 3.99% 2.21% 3.84% 3.21% 3.47% 4.32% 4.49%
Enterprise Value to Invested Capital (EV/IC)
1.56 1.80 1.68 1.81 2.07 2.66 2.19 1.96 1.83 1.88 1.84
Enterprise Value to Revenue (EV/Rev)
3.82 3.90 3.67 3.90 4.64 5.93 4.57 4.28 3.80 3.81 3.47
Enterprise Value to EBITDA (EV/EBITDA)
13.54 13.47 11.61 12.81 17.18 23.75 16.50 15.37 15.01 13.86 12.88
Enterprise Value to EBIT (EV/EBIT)
20.83 20.36 16.11 17.94 26.06 37.07 23.85 22.28 22.16 20.09 18.44
Enterprise Value to NOPAT (EV/NOPAT)
25.20 24.64 30.34 21.24 23.62 42.76 27.44 34.55 31.25 25.73 24.78
Enterprise Value to Operating Cash Flow (EV/OCF)
21.12 16.86 23.46 17.00 18.54 28.63 19.71 22.13 18.14 18.13 17.23
Enterprise Value to Free Cash Flow (EV/FCFF)
29.17 10.83 39.29 22.59 20.19 103.53 23.39 64.91 26.93 27.79 30.86
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.60 0.66 0.51 0.50 0.49 0.51 0.46 0.47 0.50 0.59 0.56
Long-Term Debt to Equity
0.58 0.52 0.47 0.49 0.43 0.51 0.39 0.47 0.47 0.53 0.52
Financial Leverage
0.33 0.32 0.28 0.30 0.29 0.29 0.28 0.29 0.33 0.37 0.39
Leverage Ratio
1.96 1.95 1.89 1.79 1.78 1.79 1.76 1.74 1.77 1.84 1.88
Compound Leverage Factor
1.61 1.57 1.57 1.40 1.41 1.45 1.60 1.56 1.54 1.63 1.68
Debt to Total Capital
37.40% 39.92% 33.63% 33.53% 32.77% 33.84% 31.38% 32.05% 33.17% 37.14% 35.83%
Short-Term Debt to Total Capital
1.19% 8.98% 2.69% 1.11% 3.67% 0.01% 4.87% 0.03% 1.45% 3.74% 2.29%
Long-Term Debt to Total Capital
36.20% 30.94% 30.95% 32.42% 29.10% 33.82% 26.51% 32.02% 31.72% 33.40% 33.54%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.15% 0.13% 0.16% 0.18% 0.22% 0.22% 0.24% 0.27% 0.30% 0.78%
Common Equity to Total Capital
62.60% 59.93% 66.23% 66.31% 67.05% 65.94% 68.39% 67.72% 66.56% 62.56% 63.39%
Debt to EBITDA
3.82 3.88 2.72 2.72 3.18 3.51 2.75 2.80 3.05 3.09 2.85
Net Debt to EBITDA
2.27 2.29 1.54 1.66 1.77 2.07 1.54 1.89 2.07 2.12 1.91
Long-Term Debt to EBITDA
3.70 3.01 2.50 2.63 2.82 3.51 2.32 2.80 2.92 2.78 2.67
Debt to NOPAT
7.11 7.10 7.11 4.52 4.37 6.31 4.57 6.30 6.35 5.74 5.48
Net Debt to NOPAT
4.22 4.19 4.01 2.76 2.44 3.73 2.57 4.24 4.32 3.94 3.68
Long-Term Debt to NOPAT
6.88 5.51 6.54 4.37 3.88 6.31 3.86 6.29 6.08 5.17 5.13
Altman Z-Score
2.12 2.10 2.53 2.75 2.91 3.46 3.23 2.98 2.79 2.71 2.79
Noncontrolling Interest Sharing Ratio
0.00% 0.12% 0.22% 0.22% 0.25% 0.30% 0.33% 0.34% 0.38% 0.44% 0.85%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.29 1.74 2.28 2.59 2.13 2.65 1.86 2.39 2.03 1.85 2.13
Quick Ratio
2.54 1.35 1.71 1.90 1.50 1.91 1.30 1.54 1.31 1.20 1.36
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
3,779 10,711 2,796 5,272 6,645 1,726 6,191 2,059 4,571 4,597 4,093
Operating Cash Flow to CapEx
498.85% 548.64% 438.58% 617.90% 596.37% 460.52% 536.99% 413.91% 427.66% 378.91% 384.98%
Free Cash Flow to Firm to Interest Expense
2.73 9.79 2.44 3.65 6.09 1.87 11.19 3.24 6.36 6.31 5.72
Operating Cash Flow to Interest Expense
3.76 6.29 4.09 4.85 6.62 6.75 13.28 9.50 9.44 9.66 10.25
Operating Cash Flow Less CapEx to Interest Expense
3.01 5.14 3.16 4.07 5.51 5.28 10.81 7.20 7.23 7.11 7.59
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.28 0.30 0.31 0.34 0.32 0.33 0.34 0.34 0.36 0.37 0.39
Accounts Receivable Turnover
5.40 5.33 5.17 5.01 5.32 5.96 5.75 5.41 5.34 5.31 5.53
Inventory Turnover
2.64 2.73 2.62 2.50 2.36 2.45 2.27 2.16 2.13 2.18 2.23
Fixed Asset Turnover
6.04 6.46 6.68 6.59 6.09 0.00 0.00 5.69 5.53 5.17 5.10
Accounts Payable Turnover
5.51 5.69 5.70 5.11 4.77 5.11 4.63 4.34 4.42 4.79 5.00
Days Sales Outstanding (DSO)
67.56 68.51 70.54 72.92 68.59 61.25 63.43 67.50 68.38 68.80 66.04
Days Inventory Outstanding (DIO)
138.46 133.74 139.22 146.16 154.58 148.71 160.63 168.71 171.01 167.77 163.94
Days Payable Outstanding (DPO)
66.26 64.09 64.07 71.39 76.47 71.41 78.83 84.07 82.53 76.24 73.07
Cash Conversion Cycle (CCC)
139.77 138.16 145.70 147.69 146.69 138.54 145.23 152.13 156.86 160.33 156.91
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
70,531 64,527 65,352 65,688 64,721 67,174 66,260 68,070 67,438 67,806 68,811
Invested Capital Turnover
0.41 0.44 0.46 0.47 0.44 0.46 0.47 0.46 0.48 0.50 0.53
Increase / (Decrease) in Invested Capital
595 -6,004 825 336 -967 2,453 -914 1,810 -632 368 1,005
Enterprise Value (EV)
110,230 115,990 109,878 119,123 134,143 178,677 144,780 133,669 123,106 127,722 126,323
Market Capitalization
91,762 96,135 95,246 103,526 120,159 162,931 131,068 117,082 105,881 107,939 106,973
Book Value per Share
$37.16 $36.68 $37.42 $37.35 $37.86 $38.15 $39.17 $38.70 $37.82 $37.45 $38.53
Tangible Book Value per Share
($11.66) ($8.56) ($7.78) ($7.78) ($6.09) ($6.14) ($2.64) ($3.60) ($3.01) ($4.19) ($2.55)
Total Capital
83,165 83,771 76,579 75,536 75,669 77,991 76,836 76,029 75,444 76,772 78,033
Total Debt
31,102 33,441 25,757 25,324 24,797 26,389 24,114 24,364 25,024 28,516 27,961
Total Long-Term Debt
30,109 25,921 23,699 24,486 22,021 26,378 20,372 24,344 23,932 25,642 26,173
Net Debt
18,468 19,733 14,530 15,476 13,849 15,572 13,541 16,405 17,019 19,551 18,741
Capital Expenditures (CapEx)
1,046 1,254 1,068 1,134 1,213 1,355 1,368 1,459 1,587 1,859 1,904
Debt-free, Cash-free Net Working Capital (DFCFNWC)
4,794 4,421 3,727 4,485 3,493 3,233 3,834 4,685 4,233 4,844 5,697
Debt-free Net Working Capital (DFNWC)
17,428 18,129 14,954 14,333 14,441 14,050 14,407 12,644 12,238 13,809 14,917
Net Working Capital (NWC)
16,435 10,609 12,896 13,495 11,665 14,039 10,665 12,624 11,146 10,935 13,129
Net Nonoperating Expense (NNE)
836 683 526 958 872 549 215 85 234 274 261
Net Nonoperating Obligations (NNO)
18,468 14,197 14,530 15,476 13,849 15,572 13,538 16,405 17,018 19,550 18,739
Total Depreciation and Amortization (D&A)
2,849 2,917 2,644 2,659 2,663 2,702 2,707 2,697 2,647 2,861 2,958
Debt-free, Cash-free Net Working Capital to Revenue
16.63% 14.88% 12.44% 14.68% 12.08% 10.73% 12.10% 15.00% 13.08% 14.44% 15.67%
Debt-free Net Working Capital to Revenue
60.44% 61.02% 49.92% 46.91% 49.95% 46.65% 45.47% 40.49% 37.81% 41.18% 41.02%
Net Working Capital to Revenue
57.00% 35.71% 43.05% 44.16% 40.35% 46.61% 33.66% 40.43% 34.44% 32.61% 36.10%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$2.51 $2.92 $2.29 $3.44 $3.57 $2.68 $3.75 $2.83 $2.77 $3.63 $3.75
Adjusted Weighted Average Basic Shares Outstanding
1.41B 1.38B 1.36B 1.35B 1.34B 1.34B 1.34B 1.33B 1.33B 1.29B 1.28B
Adjusted Diluted Earnings per Share
$2.48 $2.89 $2.27 $3.41 $3.54 $2.66 $3.73 $2.82 $2.76 $3.61 $3.73
Adjusted Weighted Average Diluted Shares Outstanding
1.43B 1.39B 1.37B 1.36B 1.35B 1.35B 1.35B 1.33B 1.33B 1.29B 1.29B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $3.57 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.39B 1.36B 1.35B 1.34B 1.34B 1.34B 1.33B 1.33B 1.28B 1.28B 1.28B
Normalized Net Operating Profit after Tax (NOPAT)
4,863 5,234 3,671 5,934 3,655 4,562 5,419 4,113 4,226 5,451 5,383
Normalized NOPAT Margin
16.87% 17.62% 12.26% 19.42% 12.64% 15.15% 17.10% 13.17% 13.06% 16.26% 14.80%
Pre Tax Income Margin
15.04% 15.49% 18.95% 17.01% 14.02% 12.93% 17.41% 17.18% 14.95% 16.78% 16.87%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
3.82 5.21 5.95 4.60 4.71 5.21 10.98 9.43 7.73 8.72 9.58
NOPAT to Interest Expense
3.16 4.30 3.16 3.88 5.20 4.52 9.54 6.08 5.48 6.81 7.13
EBIT Less CapEx to Interest Expense
3.06 4.06 5.02 3.81 3.60 3.75 8.50 7.14 5.52 6.17 6.92
NOPAT Less CapEx to Interest Expense
2.40 3.16 2.23 3.10 4.09 3.05 7.07 3.79 3.27 4.26 4.47
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
60.46% 59.05% 80.58% 57.91% 60.22% 85.95% 66.83% 95.56% 98.95% 76.51% 75.23%
Augmented Payout Ratio
140.45% 147.12% 150.73% 119.78% 87.81% 103.91% 117.09% 112.61% 156.65% 145.47% 96.63%

Quarterly Metrics And Ratios for Medtronic

This table displays calculated financial ratios and metrics derived from Medtronic's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 10/27/2023 1/26/2024 4/26/2024 7/26/2024 10/25/2024 1/24/2025 4/25/2025 7/25/2025 10/24/2025 1/23/2026 4/24/2026
DEI Shares Outstanding
- - - - - - - - - - 1,283,884,964.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 1,283,884,964.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 0.97
Growth Metrics
- - - - - - - - - - -
Revenue Growth
5.26% 4.68% 0.53% 2.77% 5.25% 2.51% 3.94% 8.38% 6.64% 8.74% 9.87%
EBITDA Growth
-0.82% 4.01% -29.17% 4.02% 12.79% 4.03% 32.94% 6.15% 3.27% -2.83% 19.77%
EBIT Growth
-1.26% 7.72% -39.13% 6.77% 18.34% 3.49% 35.73% 3.00% 0.57% -7.74% 39.97%
NOPAT Growth
111.87% 8.26% -32.21% 25.16% 40.63% 3.39% 49.10% 10.01% 11.59% -13.90% 6.13%
Net Income Growth
109.43% 8.79% -44.49% 31.62% 40.29% -2.54% 60.76% -0.19% 8.06% -11.74% 18.66%
EPS Growth
112.50% 7.61% -43.18% 35.59% 45.59% 2.02% 62.00% 1.25% 8.08% -11.88% 18.52%
Operating Cash Flow Growth
-28.31% 57.18% 12.89% 12.69% 44.93% 3.96% -8.97% 10.34% -3.44% 6.69% 1.78%
Free Cash Flow Firm Growth
-365.08% 252.75% 335.82% 401.12% 252.02% 77.75% -41.65% -46.30% -29.51% -68.58% -66.79%
Invested Capital Growth
2.60% 0.36% -0.93% -0.42% 0.09% -0.81% 0.55% 0.64% 0.84% 0.86% 1.48%
Revenue Q/Q Growth
3.66% 1.32% 6.18% -7.85% 6.17% -1.32% 7.66% -3.91% 4.46% 0.62% 8.77%
EBITDA Q/Q Growth
7.44% 6.60% -25.86% 22.49% 16.50% -1.68% -5.25% -2.20% 13.34% -7.49% 16.80%
EBIT Q/Q Growth
11.16% 11.11% -36.27% 35.63% 23.21% -2.83% -16.41% 2.92% 20.30% -10.85% 26.81%
NOPAT Q/Q Growth
10.17% 44.88% -39.73% 30.10% 23.79% 6.51% -13.08% -4.01% 25.56% -17.81% 7.14%
Net Income Q/Q Growth
14.30% 46.76% -50.64% 58.94% 21.83% 1.96% -18.57% -1.32% 31.90% -16.73% 9.48%
EPS Q/Q Growth
15.25% 45.59% -49.49% 60.00% 23.75% 2.02% -19.80% 0.00% 32.10% -16.82% 7.87%
Operating Cash Flow Q/Q Growth
-24.46% 274.28% 12.25% -64.49% -2.84% 168.48% -1.71% -56.96% -14.98% 196.65% -6.23%
Free Cash Flow Firm Q/Q Growth
-83.70% 233.69% 31.50% -6.76% -7.26% 56.32% -56.83% -14.19% 21.72% -30.33% -54.37%
Invested Capital Q/Q Growth
0.76% -0.20% -2.06% 1.10% 1.28% -1.09% -0.72% 1.20% 1.47% -1.07% -0.11%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
65.42% 65.61% 64.55% 65.12% 64.94% 66.49% 64.76% 65.02% 65.84% 63.84% 65.35%
EBITDA Margin
27.13% 28.54% 19.93% 26.49% 29.07% 28.97% 25.50% 25.95% 28.16% 25.88% 27.79%
Operating Margin
16.78% 18.33% 12.26% 16.15% 18.98% 19.85% 16.09% 16.85% 18.81% 16.24% 19.09%
EBIT Margin
18.71% 20.52% 12.32% 18.13% 21.04% 20.72% 16.09% 17.23% 19.84% 17.58% 20.49%
Profit (Net Income) Margin
11.41% 16.53% 7.68% 13.25% 15.21% 15.71% 11.89% 12.21% 15.41% 12.75% 12.84%
Tax Burden Percent
69.38% 90.83% 77.10% 82.73% 81.98% 84.61% 84.14% 80.41% 86.47% 81.91% 68.69%
Interest Burden Percent
87.88% 88.67% 80.91% 88.36% 88.18% 89.64% 87.81% 88.09% 89.82% 88.58% 91.19%
Effective Tax Rate
30.62% 9.17% 22.90% 17.35% 18.02% 15.39% 15.70% 19.59% 13.46% 18.09% 31.37%
Return on Invested Capital (ROIC)
5.46% 7.83% 4.52% 6.36% 7.44% 8.13% 6.73% 6.77% 8.16% 6.88% 6.97%
ROIC Less NNEP Spread (ROIC-NNEP)
5.35% 7.77% 3.61% 6.32% 7.28% 7.63% 5.91% 6.21% 7.78% 6.62% 6.84%
Return on Net Nonoperating Assets (RNNOA)
1.68% 2.54% 1.18% 2.36% 2.73% 2.67% 2.19% 2.61% 3.28% 2.57% 2.66%
Return on Equity (ROE)
7.14% 10.37% 5.70% 8.72% 10.17% 10.80% 8.91% 9.38% 11.44% 9.45% 9.64%
Cash Return on Invested Capital (CROIC)
3.63% 5.93% 6.75% 6.50% 6.49% 7.49% 6.80% 6.77% 6.70% 6.48% 5.99%
Operating Return on Assets (OROA)
6.52% 7.17% 4.41% 6.54% 7.71% 7.61% 5.94% 6.52% 7.60% 6.87% 8.07%
Return on Assets (ROA)
3.98% 5.78% 2.75% 4.78% 5.57% 5.77% 4.39% 4.62% 5.91% 4.99% 5.05%
Return on Common Equity (ROCE)
7.12% 10.33% 5.67% 8.69% 10.13% 10.75% 8.87% 9.34% 11.39% 9.41% 9.55%
Return on Equity Simple (ROE_SIMPLE)
8.02% 8.18% 0.00% 8.25% 8.92% 8.69% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
930 1,347 812 1,056 1,308 1,393 1,211 1,162 1,459 1,199 1,285
NOPAT Margin
11.65% 16.65% 9.45% 13.35% 15.56% 16.80% 13.56% 13.55% 16.28% 13.30% 13.10%
Net Nonoperating Expense Percent (NNEP)
0.12% 0.06% 0.91% 0.04% 0.16% 0.50% 0.82% 0.57% 0.38% 0.26% 0.13%
Return On Investment Capital (ROIC_SIMPLE)
- 1.75% - - - 1.83% 1.58% 1.51% 1.87% 1.55% 1.65%
Cost of Revenue to Revenue
34.58% 34.39% 35.45% 34.88% 35.06% 33.51% 35.24% 34.98% 34.16% 36.17% 34.65%
SG&A Expenses to Revenue
33.64% 33.04% 32.18% 33.54% 32.81% 32.77% 30.47% 32.71% 33.09% 32.78% 31.17%
R&D to Revenue
8.74% 8.59% 7.85% 8.54% 8.29% 8.14% 7.66% 8.46% 8.41% 8.01% 6.84%
Operating Expenses to Revenue
48.63% 47.27% 52.29% 48.95% 45.97% 46.65% 48.66% 48.18% 47.03% 47.61% 46.26%
Earnings before Interest and Taxes (EBIT)
1,494 1,660 1,058 1,435 1,768 1,718 1,436 1,478 1,778 1,585 2,010
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,166 2,309 1,712 2,097 2,443 2,402 2,276 2,226 2,523 2,334 2,726
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.74 2.15 2.11 2.10 2.40 2.34 2.25 2.49 2.47 2.64 2.16
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.80 3.44 3.27 3.10 3.52 3.48 3.22 3.48 3.46 3.64 2.94
Price to Earnings (P/E)
21.78 26.48 28.80 25.70 27.09 27.15 23.15 25.55 25.22 28.04 22.28
Dividend Yield
4.08% 3.29% 3.46% 3.52% 3.07% 3.09% 3.33% 3.02% 3.01% 2.81% 3.41%
Earnings Yield
4.59% 3.78% 3.47% 3.89% 3.69% 3.68% 4.32% 3.91% 3.97% 3.57% 4.49%
Enterprise Value to Invested Capital (EV/IC)
1.55 1.86 1.83 1.78 1.98 1.97 1.88 2.04 2.03 2.17 1.84
Enterprise Value to Revenue (EV/Rev)
3.34 3.97 3.80 3.72 4.14 4.05 3.81 4.09 4.06 4.21 3.47
Enterprise Value to EBITDA (EV/EBITDA)
12.12 14.41 15.01 14.62 15.97 15.55 13.86 14.96 14.97 15.94 12.88
Enterprise Value to EBIT (EV/EBIT)
17.47 20.58 22.16 21.45 23.09 22.51 20.09 21.85 22.02 23.77 18.44
Enterprise Value to NOPAT (EV/NOPAT)
25.32 29.67 31.25 29.17 30.15 29.41 25.73 27.56 27.00 29.66 24.78
Enterprise Value to Operating Cash Flow (EV/OCF)
19.19 19.84 18.14 17.56 19.00 18.45 18.13 19.56 19.84 20.48 17.23
Enterprise Value to Free Cash Flow (EV/FCFF)
43.26 31.48 26.93 27.26 30.54 26.21 27.79 30.18 30.37 33.57 30.86
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.49 0.48 0.50 0.58 0.58 0.54 0.59 0.59 0.60 0.57 0.56
Long-Term Debt to Equity
0.46 0.46 0.47 0.55 0.51 0.48 0.53 0.54 0.57 0.57 0.52
Financial Leverage
0.31 0.33 0.33 0.37 0.38 0.35 0.37 0.42 0.42 0.39 0.39
Leverage Ratio
1.77 1.79 1.77 1.81 1.79 1.78 1.84 1.88 1.86 1.84 1.88
Compound Leverage Factor
1.55 1.58 1.43 1.60 1.58 1.60 1.62 1.65 1.67 1.63 1.71
Debt to Total Capital
32.69% 32.63% 33.17% 36.65% 36.77% 34.91% 37.14% 37.28% 37.33% 36.33% 35.83%
Short-Term Debt to Total Capital
1.75% 1.33% 1.45% 2.04% 4.83% 3.44% 3.74% 3.17% 1.82% 0.25% 2.29%
Long-Term Debt to Total Capital
30.94% 31.30% 31.72% 34.61% 31.94% 31.47% 33.40% 34.11% 35.51% 36.08% 33.54%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.24% 0.26% 0.27% 0.28% 0.29% 0.30% 0.30% 0.31% 0.26% 0.27% 0.78%
Common Equity to Total Capital
67.07% 67.11% 66.56% 63.07% 62.94% 64.79% 62.56% 62.41% 62.41% 63.40% 63.39%
Debt to EBITDA
2.84 2.83 3.05 3.36 3.31 3.07 3.09 3.06 3.09 3.00 2.85
Net Debt to EBITDA
1.97 1.89 2.07 2.42 2.38 2.16 2.12 2.19 2.20 2.10 1.91
Long-Term Debt to EBITDA
2.69 2.71 2.92 3.18 2.87 2.77 2.78 2.80 2.94 2.98 2.67
Debt to NOPAT
5.94 5.82 6.35 6.71 6.24 5.82 5.74 5.64 5.57 5.58 5.48
Net Debt to NOPAT
4.11 3.90 4.32 4.82 4.48 4.08 3.94 4.04 3.97 3.91 3.68
Long-Term Debt to NOPAT
5.62 5.58 6.08 6.34 5.42 5.24 5.17 5.16 5.30 5.54 5.13
Altman Z-Score
2.44 2.78 2.63 2.50 2.74 2.78 2.53 2.74 2.82 2.97 2.62
Noncontrolling Interest Sharing Ratio
0.35% 0.37% 0.38% 0.40% 0.41% 0.43% 0.44% 0.47% 0.44% 0.44% 0.85%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.29 2.30 2.03 2.13 1.84 1.90 1.85 2.01 2.42 2.54 2.13
Quick Ratio
1.42 1.46 1.31 1.35 1.17 1.19 1.20 1.25 1.48 1.55 1.36
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-821 1,098 1,444 1,346 1,249 1,952 843 723 880 613 280
Operating Cash Flow to CapEx
143.38% 715.03% 651.88% 189.62% 237.13% 540.34% 550.76% 215.87% 197.65% 618.02% 527.25%
Free Cash Flow to Firm to Interest Expense
-4.56 5.84 7.11 8.06 5.97 10.90 4.84 4.11 4.86 3.39 1.58
Operating Cash Flow to Interest Expense
3.67 13.16 13.68 5.90 4.58 14.37 14.53 6.18 5.11 15.16 14.54
Operating Cash Flow Less CapEx to Interest Expense
1.11 11.32 11.58 2.79 2.65 11.71 11.89 3.32 2.52 12.71 11.78
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.35 0.35 0.36 0.36 0.37 0.37 0.37 0.38 0.38 0.39 0.39
Accounts Receivable Turnover
5.53 5.45 5.34 5.51 5.41 5.50 5.31 5.57 5.50 5.69 5.53
Inventory Turnover
2.05 2.01 2.13 2.05 2.05 2.03 2.18 2.10 2.06 2.09 2.23
Fixed Asset Turnover
5.79 5.73 5.53 5.45 5.42 5.34 5.17 5.15 5.11 5.15 5.10
Accounts Payable Turnover
5.06 5.31 4.42 5.01 5.07 5.39 4.79 4.90 4.84 5.14 5.00
Days Sales Outstanding (DSO)
66.02 66.94 68.38 66.20 67.44 66.42 68.80 65.50 66.41 64.16 66.04
Days Inventory Outstanding (DIO)
178.41 181.70 171.01 178.21 177.74 179.41 167.77 173.71 177.14 174.45 163.94
Days Payable Outstanding (DPO)
72.16 68.76 82.53 72.85 71.99 67.71 76.24 74.49 75.47 71.06 73.07
Cash Conversion Cycle (CCC)
172.26 179.88 156.86 171.56 173.19 178.13 160.33 164.71 168.09 167.55 156.91
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
68,994 68,858 67,438 68,181 69,053 68,299 67,806 68,620 69,632 68,885 68,811
Invested Capital Turnover
0.47 0.47 0.48 0.48 0.48 0.48 0.50 0.50 0.50 0.52 0.53
Increase / (Decrease) in Invested Capital
1,751 249 -632 -290 59 -559 368 439 579 586 1,005
Enterprise Value (EV)
106,886 128,334 123,106 121,150 136,740 134,562 127,722 139,809 141,126 149,229 126,323
Market Capitalization
89,353 111,269 105,881 100,915 116,181 115,649 107,939 119,081 120,149 129,330 106,973
Book Value per Share
$38.68 $38.95 $37.82 $37.39 $37.81 $38.52 $37.45 $37.38 $37.93 $38.21 $38.53
Tangible Book Value per Share
($2.57) ($2.30) ($3.01) ($4.64) ($3.97) ($2.82) ($4.19) ($4.17) ($3.06) ($2.53) ($2.55)
Total Capital
76,727 77,178 75,444 76,025 77,042 76,222 76,772 76,742 77,957 77,267 78,033
Total Debt
25,080 25,182 25,024 27,865 28,326 26,607 28,516 28,609 29,100 28,071 27,961
Total Long-Term Debt
23,741 24,153 23,932 26,312 24,607 23,985 25,642 26,179 27,680 27,880 26,173
Net Debt
17,346 16,861 17,019 20,022 20,337 18,685 19,551 20,488 20,773 19,688 18,741
Capital Expenditures (CapEx)
461 346 426 520 404 476 459 504 468 444 488
Debt-free, Cash-free Net Working Capital (DFCFNWC)
6,027 5,428 4,233 5,370 5,973 5,373 4,844 6,002 7,154 6,384 5,697
Debt-free Net Working Capital (DFNWC)
13,761 13,749 12,238 13,213 13,962 13,295 13,809 14,123 15,481 14,767 14,917
Net Working Capital (NWC)
12,422 12,720 11,146 11,660 10,243 10,673 10,935 11,693 14,061 14,576 13,129
Net Nonoperating Expense (NNE)
19 9.99 152 7.26 30 90 150 115 78 49 26
Net Nonoperating Obligations (NNO)
17,347 16,862 17,018 20,021 20,337 18,684 19,550 20,487 20,775 19,689 18,739
Total Depreciation and Amortization (D&A)
672 649 654 662 675 684 840 748 745 749 716
Debt-free, Cash-free Net Working Capital to Revenue
18.86% 16.80% 13.08% 16.48% 18.10% 16.18% 14.44% 17.55% 20.58% 17.99% 15.67%
Debt-free Net Working Capital to Revenue
43.06% 42.54% 37.81% 40.56% 42.31% 40.05% 41.18% 41.30% 44.54% 41.62% 41.02%
Net Working Capital to Revenue
38.87% 39.36% 34.44% 35.79% 31.04% 32.15% 32.61% 34.19% 40.45% 41.08% 36.10%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.68 $0.99 $0.51 $0.81 $0.99 $1.01 $0.82 $0.81 $1.07 $0.89 $0.98
Adjusted Weighted Average Basic Shares Outstanding
1.33B 1.33B 1.33B 1.29B 1.28B 1.28B 1.29B 1.28B 1.28B 1.28B 1.28B
Adjusted Diluted Earnings per Share
$0.68 $0.99 $0.50 $0.80 $0.99 $1.01 $0.81 $0.81 $1.07 $0.89 $0.96
Adjusted Weighted Average Diluted Shares Outstanding
1.33B 1.33B 1.33B 1.30B 1.29B 1.29B 1.29B 1.29B 1.29B 1.29B 1.29B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.33B 1.33B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B 1.28B
Normalized Net Operating Profit after Tax (NOPAT)
1,003 1,365 932 1,162 1,332 1,448 1,515 1,220 1,468 1,313 1,382
Normalized NOPAT Margin
12.56% 16.88% 10.85% 14.68% 15.85% 17.46% 16.97% 14.22% 16.38% 14.56% 14.09%
Pre Tax Income Margin
16.45% 18.20% 9.97% 16.02% 18.55% 18.57% 14.13% 15.18% 17.82% 15.57% 18.69%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
8.30 8.83 5.21 8.59 8.46 9.60 8.25 8.40 9.82 8.76 11.36
NOPAT to Interest Expense
5.17 7.16 4.00 6.32 6.26 7.78 6.96 6.60 8.06 6.63 7.26
EBIT Less CapEx to Interest Expense
5.74 6.99 3.11 5.48 6.53 6.94 5.61 5.53 7.24 6.30 8.60
NOPAT Less CapEx to Interest Expense
2.60 5.32 1.90 3.21 4.32 5.12 4.32 3.74 5.48 4.17 4.50
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
88.34% 86.40% 98.95% 92.14% 83.83% 84.03% 76.51% 76.80% 75.42% 78.21% 75.23%
Augmented Payout Ratio
101.58% 100.73% 156.65% 205.31% 188.83% 191.00% 145.47% 95.27% 95.24% 97.05% 96.63%

Financials Breakdown Chart

Key Financial Trends

Medtronic’s latest quarter shows steady top-line growth and solid profitability, but operating cash flow has been a bit choppy and the balance sheet remains heavily levered. Revenue and earnings improved year over year in fiscal Q4 2026, while the company continued to generate strong free cash flow despite ongoing dividend, buyback, and debt obligations.

  • Revenue is still growing: Q4 2026 revenue rose to $9.81 billion from $8.93 billion in Q4 2025, and Q3 2026 revenue also improved year over year. That suggests the business is still expanding.
  • Profitability improved year over year in the latest quarter: Q4 2026 operating income was $1.87 billion versus $1.44 billion a year earlier, and net income attributable to common shareholders increased to $1.24 billion from $1.06 billion.
  • Margins held up well: Gross profit in Q4 2026 was $6.41 billion on revenue of $9.81 billion, which points to a healthy gross margin profile for a mature med-tech company.
  • Operating cash flow remains strong: Medtronic produced $2.57 billion of operating cash flow in Q4 2026 and $1.09 billion in Q1 2026, which supports dividends, capex, and debt service.
  • Cash balance and liquid assets remain meaningful: As of Q3 2026, Medtronic had $1.15 billion in cash and $7.24 billion in short-term investments, giving it liquidity even with debt on the books.
  • Debt has come down somewhat from earlier periods: Long-term debt was $27.88 billion in Q3 2026 versus $24.44 billion in Q1 2024, but short-term debt is lower than some prior quarters and the company has been actively managing maturities.
  • Share count is relatively stable: Diluted weighted-average shares were 1.289 billion in Q4 2026 versus 1.290 billion in Q3 2026, so buybacks have not dramatically changed the share base recently.
  • Medtronic continues to return capital: The company paid roughly $900 million in dividends each quarter and also repurchased shares, which is shareholder-friendly but consumes cash.
  • Recent results show some quarter-to-quarter volatility: Operating cash flow swung from $925 million in Q2 2026 to $2.57 billion in Q4 2026, indicating working-capital timing can materially affect reported cash generation.
  • Margins are being pressured by operating expenses and special charges: SG&A, R&D, amortization, restructuring, and special charges remain sizable, and these costs can weigh on operating leverage.
  • Interest expense is still a drag: Interest expense was about $177 million in Q4 2026, and the business continues to carry a large debt load.
  • Balance sheet leverage remains elevated: Total liabilities were $42.29 billion versus total common equity of $48.99 billion in Q3 2026, so the company is not lightly levered.
  • AOCI remains deeply negative: Accumulated other comprehensive loss was about $(4.33) billion in Q3 2026, reflecting persistent balance-sheet pressure from items below net income.

Bottom line: Medtronic looks fundamentally stable, with moderate revenue growth, resilient profits, and strong cash generation. The main things investors should watch are operating margin trends, working-capital swings, and whether debt reduction can keep pace with ongoing capital returns.

07/06/26 03:17 AM ETAI Generated. May Contain Errors.

Medtronic Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Medtronic's fiscal year ends in April. Their fiscal year 2026 ended on April 24, 2026.

Medtronic's net income appears to be on an upward trend, with a most recent value of $4.84 billion in 2026, rising from $3.54 billion in 2016. The previous period was $4.69 billion in 2025. Check out Medtronic's forecast to explore projected trends and price targets.

Medtronic's total operating income in 2026 was $6.47 billion, based on the following breakdown:
  • Total Gross Profit: $23.64 billion
  • Total Operating Expenses: $17.18 billion

Over the last 10 years, Medtronic's total revenue changed from $28.83 billion in 2016 to $36.36 billion in 2026, a change of 26.1%.

Medtronic's total liabilities were at $42.96 billion at the end of 2026, a 1.1% decrease from 2025, and a 9.7% decrease since 2016.

In the past 10 years, Medtronic's cash and equivalents has ranged from $1.28 billion in 2024 to $4.97 billion in 2017, and is currently $1.95 billion as of their latest financial filing in 2026.

Over the last 10 years, Medtronic's book value per share changed from 37.16 in 2016 to 38.53 in 2026, a change of 3.7%.



Financial statements for NYSE:MDT last updated on 6/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners